Difference between revisions of "Vinorelbine (Navelbine)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or" to "or") |
||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase. Vinorelbine may possibly also disrupt: amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent calcium transport ATPase activity; and DNA/RNA and lipid synthesis.<ref name="insert">[http://www.pierre-fabre.com/us/file/nvb_prescribing_info_us.pdf Vinorelbine (Navelbine) package insert]</ref><ref>[ | + | Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase. Vinorelbine may possibly also disrupt: amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent calcium transport ATPase activity; and DNA/RNA and lipid synthesis.<ref name="insert">[http://www.pierre-fabre.com/us/file/nvb_prescribing_info_us.pdf Vinorelbine (Navelbine) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/vinorelbine.pdf Vinorelbine (Navelbine) package insert (locally hosted backup)]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: [[vesicant]] | <br>Extravasation: [[vesicant]] | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.<ref name="insert"></ref> |
==Disease for which it is used== | ==Disease for which it is used== | ||
| Line 11: | Line 11: | ||
*[[Diffuse large B-cell lymphoma]] | *[[Diffuse large B-cell lymphoma]] | ||
*[[Esophageal cancer]] | *[[Esophageal cancer]] | ||
| − | *[[Hodgkin lymphoma]] | + | **[[Esophageal squamous cell carcinoma]] |
| + | *[[Classical Hodgkin lymphoma]] | ||
*[[Malignant pleural mesothelioma]] | *[[Malignant pleural mesothelioma]] | ||
*[[Non-small cell lung cancer]] | *[[Non-small cell lung cancer]] | ||
| Line 25: | Line 26: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
* 1994-12-23: Initial FDA approval as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced [[non-small cell lung cancer|non-small cell lung cancer (NSCLC)]]. ''(Based on Crawford et al. 1996, Le Chevalier et al. 1994, SWOG S9308)'' | * 1994-12-23: Initial FDA approval as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced [[non-small cell lung cancer|non-small cell lung cancer (NSCLC)]]. ''(Based on Crawford et al. 1996, Le Chevalier et al. 1994, SWOG S9308)'' | ||
| + | ==History of changes in EMA indication== | ||
| + | *1989-04-11: EURD | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2005-05-31: New indication for the treatment of inoperable or recurrent [[breast cancer]]. | ||
==Also known as== | ==Also known as== | ||
| Line 46: | Line 51: | ||
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
| − | [[Category:Hodgkin lymphoma medications]] | + | [[Category:Esophageal squamous cell carcinoma medications]] |
| + | [[Category:Classical Hodgkin lymphoma medications]] | ||
[[Category:Malignant pleural mesothelioma medications]] | [[Category:Malignant pleural mesothelioma medications]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
| Line 55: | Line 61: | ||
[[Category:FDA approved in 1994]] | [[Category:FDA approved in 1994]] | ||
| + | [[Category:EMA approved in 1989]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Latest revision as of 00:14, 6 July 2024
General information
Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase. Vinorelbine may possibly also disrupt: amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent calcium transport ATPase activity; and DNA/RNA and lipid synthesis.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.[1]
Disease for which it is used
- Breast cancer
- Cervical cancer
- Diffuse large B-cell lymphoma
- Esophageal cancer
- Classical Hodgkin lymphoma
- Malignant pleural mesothelioma
- Non-small cell lung cancer
- Ovarian cancer
- Soft tissue sarcoma
- Small cell lung cancer
Patient drug information
- Vinorelbine (Navelbine) patient drug information (Chemocare)[3]
- Vinorelbine (Navelbine) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1994-12-23: Initial FDA approval as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced non-small cell lung cancer (NSCLC). (Based on Crawford et al. 1996, Le Chevalier et al. 1994, SWOG S9308)
History of changes in EMA indication
- 1989-04-11: EURD
History of changes in PMDA indication
- 2005-05-31: New indication for the treatment of inoperable or recurrent breast cancer.
Also known as
- Code name: KW-2307
- Generic name: NVB, vinorelbine tartrate
- Brand names: Binorel, Biovelbin, Eunades, Flonorbin, Navelbine, Neoben, Relbovin, Vinelbine, Vinorelbel, Vinotec
References
Categories:
- Drugs
- Intravenous medications
- Vesicant
- Microtubule inhibitors
- Vinca alkaloids
- Breast cancer medications
- Cervical cancer medications
- Diffuse large B-cell lymphoma medications
- Esophageal cancer medications
- Esophageal squamous cell carcinoma medications
- Classical Hodgkin lymphoma medications
- Malignant pleural mesothelioma medications
- Non-small cell lung cancer medications
- Non-small cell lung cancer, nonsquamous medications
- Ovarian cancer medications
- Soft tissue sarcoma medications
- Small cell lung cancer medications
- FDA approved in 1994
- EMA approved in 1989
- WHO Essential Cancer Medicine